Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 12/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 0.74 |
| ▸ | HTR1D | P28221 | 1/20 | 0.63 |
| ▸ | HTR1B | P28222 | 1/20 | 0.63 |
| ▸ | HTR2A | P28223 | 1/20 | 0.63 |
| ▸ | HTR1E | P28566 | 1/20 | 0.63 |
| ▸ | HTR2B | P41595 | 1/20 | 0.63 |
| ▸ | HTR5A | P47898 | 1/20 | 0.63 |
| ▸ | HTR6 | P50406 | 1/20 | 0.63 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.49 |
| ▸ | CASR | P41180 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3340335 | 0.86 | HTR7 (0.75) | HTR7HTR1AHTR1DHTR1BHTR2A | |
| SCHEMBL3336197 | 0.85 | HTR7 (1.00) | HTR7HTR1AHTR1DHTR1BHTR2A | |
| SCHEMBL3337267 | 0.85 | HTR7 (0.73) | HTR7HTR1AHTR1DHTR1BHTR2A | |
| SCHEMBL12881923 | 0.83 | HTR7 (0.71) | HTR7HTR1AHTR1DHTR1BHTR2A | |
| SCHEMBL22398944 | 0.83 | HTR7 (0.71) | HTR7HTR1AFFAR1CASRDRD2 | |
| SCHEMBL9230739 | 0.82 | HTR7 (0.69) | HTR7HTR1AFFAR1CASRDRD2 | |
| SCHEMBL12806502 | 0.80 | HTR7 (0.69) | HTR7HTR1AFFAR1CASRDRD2 | |
| SCHEMBL10287112 | 0.79 | HTR7 (0.66) | HTR7HTR1AFFAR1CASRDRD2 | |
| SCHEMBL3338228 | 0.79 | HTR7 (0.74) | HTR7HTR1AHTR1DHTR1BHTR2A | |
| SCHEMBL3337703 | 0.79 | HTR7 (0.82) | HTR7HTR1AHTR1DHTR1BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2676954-A1 | Heterocyclyl-substituted-phenyl derivatives as vasodilators | Laboratorios del Dr. Esteve S.A. (ES) | 2013-12-25 | — | — | EP | claimed |
| US-20100152252-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE,S.A. (ES) | 2010-06-17 | — | — | US | claimed |
| EP-2114894-A1 | HETEROCYCLYL-SUBSTITUTED-EHYLAMINO-PHENYL DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-11-11 | — | — | EP | claimed |
| EP-1997807-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-12-03 | — | — | EP | claimed |
| WO-2008077625-A1 | HETEROCYCLYL-SUBSTITUTED-EHYLAMINO-PHENYL DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-07-03 | — | — | WO | claimed |
| EP-1935886-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-06-25 | — | — | EP | claimed |
| EP-2676954-A1 | Heterocyclyl-substituted-phenyl derivatives as vasodilators | Laboratorios del Dr. Esteve S.A. (ES) | 2013-12-25 | — | — | EP | disclosed |
| US-20100197717-A1 | COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| US-20100197717-A1 | COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| US-20100197717-A1 | COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| US-20100152252-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE,S.A. (ES) | 2010-06-17 | — | — | US | disclosed |
| US-20100152252-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE,S.A. (ES) | 2010-06-17 | — | — | US | disclosed |
| US-20100152252-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE,S.A. (ES) | 2010-06-17 | — | — | US | disclosed |
| EP-1997493-A1 | Combination of a 5-HT7 receptor ligand and an opioid receptor ligand | Laboratorios del Dr. Esteve S.A. (ES) | 2008-12-03 | — | — | EP | disclosed |
| EP-1997493-A1 | Combination of a 5-HT7 receptor ligand and an opioid receptor ligand | Laboratorios del Dr. Esteve S.A. (ES) | 2008-12-03 | — | — | EP | disclosed |
| EP-1997807-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-12-03 | — | — | EP | disclosed |
| EP-1997807-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008077625-A1 | HETEROCYCLYL-SUBSTITUTED-EHYLAMINO-PHENYL DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-07-03 | — | — | WO | disclosed |
| EP-1935886-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-06-25 | — | — | EP | disclosed |
| EP-1935886-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197717-A1 | COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND | OPRL1, OPRM1, OPRK1 | HTR7 5/4885HTR1A 8/4885HTR1D 43/4885 |
| US-20100152252-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | PKM, PKLR, HNMT | HTR7 630/4885HTR1A 1355/4885HTR1D 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.